86 related articles for article (PubMed ID: 3731151)
1. Phase II trial of bisantrene in patients with metastatic melanoma.
Mackel C; Meyskens FL; Alberts DS
Cancer Treat Rep; 1986 Aug; 70(8):1037-8. PubMed ID: 3731151
[No Abstract] [Full Text] [Related]
2. Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
Lopez M; Di Lauro L; Papaldo P; Ganzina F; Di Pietro N; Lazzaro B
Cancer Treat Rep; 1986 Jul; 70(7):911-2. PubMed ID: 3459575
[No Abstract] [Full Text] [Related]
3. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
4. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
[No Abstract] [Full Text] [Related]
5. Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.
Green MR; Vosika G; Propert KJ; Ware JH; Comis R
Cancer Treat Rep; 1986 Apr; 70(4):539-40. PubMed ID: 3698052
[No Abstract] [Full Text] [Related]
6. Phase II trial of bisantrene in advanced colorectal carcinoma.
Ahmed T; Kemeny NE; Michaelson RA; Harper HD
Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
[No Abstract] [Full Text] [Related]
7. Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
Stiff PJ; Sweet D; Kilton LJ; Johnson CM; Muntean B; Blough RR
Med Pediatr Oncol; 1991; 19(2):126-8. PubMed ID: 2011097
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of pyrazofurin in patients with metastatic sarcoma.
Gralla RJ; Sordillo PP; Magill GB
Cancer Treat Rep; 1978 Oct; 62(10):1573-4. PubMed ID: 361228
[No Abstract] [Full Text] [Related]
10. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
Fiore J; Kemeny N; Raymond V; Young C
Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
[No Abstract] [Full Text] [Related]
11. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced non-small cell lung cancer with bisantrene.
Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
[No Abstract] [Full Text] [Related]
14. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma.
Torti FM; Porzig KJ; Gandara DR; Volberding P; Mitchell E; Meyers FJ; Kohler M; Gribble M
Cancer Treat Rep; 1984 Dec; 68(12):1509-10. PubMed ID: 6595059
[No Abstract] [Full Text] [Related]
15. Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
Booth BW; Korzun AH; Weiss RB; Ellison RR; Budman D; Khojasteh A; Wood W
Cancer Treat Rep; 1986 Oct; 70(10):1247-8. PubMed ID: 3530455
[No Abstract] [Full Text] [Related]
16. Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.
Willson JK; Knuiman MW; Skeel RT; Wolter JM; Pandya KJ; Falkson G; Chang YC
Cancer Treat Rep; 1986 Oct; 70(10):1237-8. PubMed ID: 3530452
[No Abstract] [Full Text] [Related]
17. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
[No Abstract] [Full Text] [Related]
19. Phase II trial of bisantrene in patients with advanced sarcoma: a Southwest Oncology Group Study.
Cowan JD; Gehan E; Rivkin SE; Jones SE
Cancer Treat Rep; 1986 May; 70(5):685-6. PubMed ID: 3708622
[No Abstract] [Full Text] [Related]
20. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
[No Abstract] [Full Text] [Related]
[Next] [New Search]
